Researchers wanted to understand how two different pulsed field ablation (PFA) systems compare for treating persistent atrial fibrillation, a type of irregular heartbeat. They looked at data from two separate clinical trials: the SPHERE Per-AF trial (212 patients) and the ADVANTAGE AF trial (260 patients). Both trials treated patients with symptomatic persistent atrial fibrillation, but they used different PFA devices.
The analysis found that patients treated with the Sphere-9 system had a 77.4% success rate (freedom from arrhythmias) at 12 months, compared to 63.5% for those treated with the Farawave system. The Sphere-9 system also used about 14 minutes less fluoroscopy (a type of X-ray imaging) during the procedure. The rates of serious safety events were very low and similar between the two groups.
It is very important to know this was not a direct, head-to-head comparison. The researchers used a statistical method to compare results from two different trials. This means the findings are not as strong as they would be from a single trial designed to directly test both devices against each other. The results suggest there may be differences between PFA systems, but more research is needed to be sure.
